Apollo Hospitals Enterprise Limited agreed to Spin-Off 85% stake in Apollo Healthtech Limited on June 30, 2025. The shareholders of AHEL. for every 100 shares of AHEL, the shareholders of AHEL will receive 195.2 shares of Spinco. The turnover of the Identified Business Undertaking demerged division for the year ended March 31, 2025 was INR 70 billion. Apollo Healthtech Limited is proposed to be listed on BSE Limited and the National Stock Exchange of India Limited. Post completion, the New Entity to Consolidate Digital and Pharmacy Operations. Under the proposed structure, AHEL shareholders will receive 195.2 shares of the new company for every 100 shares they currently hold. AHEL will retain a 15% stake in the new entity and will nominate one board member. As of August 13, 2025, The listing could take place in the last quarter of FY2027 (January to March quarter).
The Scheme is subject to the receipt of requisite approvals, no-objections (as relevant) from the Stock Exchanges and SEBI, approval from the Insurance Regulatory and Development Authority of India, Competition Commission of India, shareholders and creditors of the company(ies) involved in the Scheme, as may be applicable, Chennai Bench of National Company Law Tribunal and such other statutory and regulatory approvals as may be required. The company plans to list the newly formed entity on the stock exchange within 18-21 months, pending shareholder and regulatory approvals. The Board of Directors of Apollo Hospitals Enterprise Limited have accorded in-principle approval for the Composite Scheme of Arrangement for a strategic restructuring. The Competition Commission of India has approved the proposed combination involving (i) demerger of the identified business undertaking of AHEL into AHTL; (ii) Merger and amalgamation of AHL and Keimed with and into AHTL; and (iii) acquisition of 74.5% shareholding of AMPL by AHTL. Apollo Hospitals Enterprise on December 24, 2025 said that it has received a letter from the National Stock Exchange with 'no objection' for its proposed demerger or composite scheme of arrangement between Apollo Hospitals Enterprise Limited, Apollo Healthco Limited , Keimed Private Limited and Apollo Healthtech Limited. As of March 26, 2026, Apollo Hospitals Enterprise Ltd. has received approval from the National Company Law Tribunal for the transaction.
Veda Corporate Advisors Private Limited acted as a financial advisor, Shardul Amarchand Mangaldas & Co, acted as a legal advisor and Axis Capital Limited provided fairness opinion to Apollo Hospitals Enterprise Limited.
Apollo Hospitals Enterprise Limited specializes in healthcare services. Net sales break down by activity as follows:
- hospital and outpatient surgical care services (54.6%): exploitation of a network of 71 hospitals (9,911 beds) at the end of March 2022;
- distribution of pharmaceutical and wellness products (36.5%): exploitation of a network of 4,529 pharmacies in India;
- healthcare and diagnostic services (8.9%): exploitation of 254 primary care clinics, 1,228 diagnostic centers, 90 dialysis centers, 95 dental clinics, 29 diabetes management clinics, 15 obstetric and pediatric clinics and 11 specialized care centers.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.